このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Evaluation of an Early Preventive and Educational Care Pathway for Moderate and Late Preterm Infants. A Randomized Controlled Study (PREKINOU)

2026年11月4日 更新者:University Hospital, Caen

Prematurity is associated with a high risk of neurodevelopmental disorders (NDDs). The prognosis for moderate and late preterm infants (32 to <37 weeks of gestational age) is better than that for very preterm infants (<32 weeks of gestational age).

According to the French National Authority for Health (Haute Autorité de Santé, HAS), moderate and late preterm (MLPT) infants are at moderate risk of NDDs. However, although their risk is lower than that of very preterm infants, it remains significant. Recent research has challenged the misconception that MLPT births are associated with little or no increase in developmental delays compared with full-term births. The risk of NDDs is two to three times higher in these infants than in infants born at term. Prematurity, regardless of its degree, affects the motor and cognitive performance of children born preterm. Impaired neurological development persists at different follow-up ages.

Moderate and late preterm infants account for 85% of all preterm births. Consequently, the number of infants with NDDs is substantial, highlighting the need for appropriate care to limit the impact on the healthcare system.

When an NDD is suspected, the HAS recommends providing parental guidance to help parents initiate activities at home while awaiting the implementation of early intervention. However, these children currently receive no standardised follow-up. The lack of specific assessment of MLPT infants, due to underestimation of their neuromotor risk, leads to delays in care. These delays may result in delayed neuromotor development and potentially long-term sequelae. Yet interventions initiated before discharge from the neonatal unit have the greatest positive impact on the neuromotor development of preterm infants.

Parental education is an effective early intervention strategy. It provides a significant opportunity to improve young children's motor, language, cognitive and socio-emotional development, as well as attachment. It also helps parents develop a better understanding of their infants and promotes parent-infant interactions.

We hypothesise that an early preventive care pathway (PREKINOU) could improve the motor development scores of MLPT infants at 9 months of corrected age.

The objective of the study is to evaluate the effectiveness of an early preventive and educational care pathway (PREKINOU) on the motor development of MLPT infants at 9 months of corrected age (41 weeks ± 14 days), compared with standard care.

This study will include 92 infants born moderately or late preterm. The infants will be randomised into two groups. Infants in the experimental group (n = 46) will follow the PREKINOU pathway in addition to standard care and mandatory medical examinations, both in the maternity unit and after discharge home, until 13 weeks of corrected age (CA).

At 9 months of corrected age (41 weeks ± 14 days), infants in both the experimental and control groups will undergo a blinded assessment using the motor, cognitive and language subscales of the Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4). The assessment will be conducted by a psychomotor therapist trained in the administration of this scale.

Parents' perceptions of their ability to care for their infants will also be assessed at 9 months of corrected age using the Maternal Perceived Parental Self-Efficacy questionnaire (PMP-SE).

The level of parental engagement in the experimental group will be measured using logbooks. Parental support for the development of infants in both the experimental and control groups will be assessed at 9 months of corrected age using a questionnaire.

調査の概要

状態

まだ募集していません

条件

介入・治療

研究の種類

介入

入学 (推定)

92

段階

  • 適用できない

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

7ヶ月~8ヶ月 (子)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Birth between 32 weeks + 0 days and 36 weeks + 6 days of gestational age at Flers Hospital or Caen University Hospital (CHU de Caen).
  • Maternal and paternal age ≥ 18 years.
  • At least one parent present in the hospital for more than 3 hours per day.
  • Residence within a 60-kilometre radius of the place of birth.
  • Parents' ability to understand and communicate in French, both orally and in writing.
  • Written informed consent signed by the legal representatives holding parental responsibility.
  • Affiliation with a social security system.

Exclusion Criteria:

  • Suspected hypoxic-ischaemic encephalopathy requiring therapeutic hypothermia.
  • Perinatal arterial ischaemic stroke, diagnosed between 20 weeks of fetal life and 28 days after birth.
  • Abnormal brain growth: microcephaly, defined as a head circumference ≤ -2 standard deviations (SD) at birth and subsequently confirmed, or macrocephaly ≥ +3 SD for gestational age, persisting after a second measurement.
  • First-degree family history of severe neurodevelopmental disorders (sibling or parent).
  • Symptomatic congenital cytomegalovirus infection or other congenital infections affecting the fetus, including toxoplasmosis, Zika virus infection and rubella.
  • Bacterial or herpesvirus encephalitis and meningoencephalitis.
  • Complex congenital heart disease requiring surgery, including transposition of the great arteries and hypoplastic left heart syndrome.
  • Prenatal exposure to a major toxic agent, including certain antiepileptic drugs or severe alcohol exposure and/or exposure associated with signs of fetal alcohol spectrum disorder.
  • Major, prolonged and repeated surgery (cardiac, cerebral, abdominal or thoracic).
  • Cortical blindness or retinopathy of prematurity resulting in blindness.
  • Congenital musculoskeletal abnormality.
  • Chromosomal or genetic abnormality.
  • Infants born to mothers or fathers with documented histories of social problems (including child abuse, neglect or parental substance misuse) or mental illness.
  • Multiple pregnancy involving three or more premature infants.
  • Bronchopulmonary dysplasia with ongoing oxygen dependency after 36 weeks of gestational age.
  • Any gastrointestinal or other condition preventing the infant from being placed in the prone position.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:防止
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Experimental group

Infants will receive early preventive and educational care pathway (PREKINOU) in addition to standard care and mandatory medical examinations

Specific early preventive and educational care pathway for moderately and late preterm (MLPT) infants.

介入なし:Control group

Infants will receive only standard care

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Motor subscale of the Bayley Scales
時間枠:9 month

Infants' motor development will be assessed at 9 months of corrected age (41 weeks ± 14 days) using the Bayley Scales of Infant and Toddler Development, Fourth Edition (2022).

Scores will be compared with the normative data from the French adaptation of the Bayley-4

9 month

二次結果の測定

結果測定
メジャーの説明
時間枠
Language and Cognitive Subscales of the Bayley-4
時間枠:9 months

Infants' language and cognitive development will be assessed at 9 months of corrected age (41 weeks ± 14 days) using the Bayley Scales of Infant and Toddler Development, Fourth Edition (2022).

Scores on the Cognitive and Language subtests will be compared with the normative data from the French adaptation of the Bayley-4.

9 months
General Movement Assessment
時間枠:13 weeks

General Movements (GMs) will be assessed on two occasions in the experimental group: immediately before discharge from hospital or the maternity unit, and at 13 weeks of corrected age (3 months). In the control group, GMs will be assessed only at 13 weeks of corrected age.

The Revised Motor Optimality Score (MOS-R) will be calculated for each infant during the video analysis of GMs performed at 13 weeks of corrected age

13 weeks
Maternal Perceived Parental Self-Efficacy Questionnaire (PMP-SE)
時間枠:9 months

Parents in both groups will complete this questionnaire at 9 months of corrected age (41 weeks ± 14 days).

9 months
Level of Parental Engagement
時間枠:From enrollment to the end of the programme"

Parents will be asked to record the frequency of activities completed each week in logbooks .

Adherence to the educational programme will be classified as follows:

  • Excellent adherence: parents complete at least two activities per day, on 5 out of 7 days.
  • Good adherence: parents complete at least two activities per day, on 3 out of 7 days.
  • Poor adherence: parents complete fewer than two activities per day, on 3 out of 7 days.
From enrollment to the end of the programme"
Questionnaire on Parental Support for the Development of MLPT Infants
時間枠:9 months

To assess the impact of the PREKINOU pathway on parental support for infant development, parents will be asked to complete a questionnaire at the final assessment, at 9 months of corrected age (41 weeks ± 14 days).

The questionnaire will address the following areas: The infant's environment, Positioning and daily routines, Sensory and motor stimulation and responses and adaptations to the infant's needs.

9 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:VIRGILE FILLION BROQUET、CMPR (Center for Physical Medicine and Rehabilitation) La Clairière

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2027年1月1日

一次修了 (推定)

2030年11月1日

研究の完了 (推定)

2030年11月1日

試験登録日

最初に提出

2026年11月4日

QC基準を満たした最初の提出物

2026年11月4日

最初の投稿 (実際)

2026年11月10日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月10日

QC基準を満たした最後の更新が送信されました

2026年11月4日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 25-0295

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。